Stock Comparison

JNJ vs TERN

Johnson & Johnson vs Terns Pharmaceuticals Inc

Who's the better investment? Let's break it down.

The Verdict

JNJ takes this one.

This one's close — only 0.9 points separating them. JNJ wins by a hair, but both deserve a closer look.

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

TERN

Terns Pharmaceuticals Inc

0.1

out of 10

Distressed

Want to compare any two stocks?

Valuation

JNJ

Metric

TERN

$557.1B

Market Cap

$6.1B

26.5

P/E Ratio

Lower may indicate better value

-51.4

28.4

Forward P/E

N/A

Profitability & Growth

JNJ

Metric

TERN

21.8%

Profit Margin

N/A

68.0%

Gross Margin

N/A

25.9%

Operating Margin

N/A

26.3%

Return on Equity

-20.0%

10.7%

Return on Assets

-19.4%

7.9%

Revenue Growth

-100.0%

$8.65

EPS

$-1.03

Financial Health

JNJ

Metric

TERN

0.6

Debt-to-Equity

Lower = less leverage

0.1

1.0

Current Ratio

Above 1.0 is healthy

62.4

0.3

Beta

Lower = less volatile

-0.4

2.3%

Dividend Yield

None

Risk Comparison

JNJ

Overall

Conservative

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for JNJ, despite its broad diversification, remains its exposure to patent expirations and increasing biosimilar competition for blockbuster drugs like Stelara, which generated over $...

Red Flags

🚩Deceleration of organic revenue growth below 4% for two consecutive quarters, signaling broader mark...
🚩Significant increase in litigation provisions or adverse judgments exceeding $5 billion in a single ...
🚩Dividend growth rate significantly slowing or pausing, indicating a fundamental shift in capital all...

TERN

Overall

Not Applicable

Financial

Not Applicable

Market

Not Applicable

Competitive

Not Applicable

Execution

Not Applicable

Regulatory

Not Applicable

What Could Go Wrong

For former shareholders, the only remaining 'risk' would have been if the Merck acquisition (announced in March 2026) had failed to close by May 5, 2026. However, the deal completed as planned, and Te...

Red Flags

🚩Company delisted on May 5, 2026.
🚩No longer trades publicly.
🚩All shareholder equity converted to cash at $53.00/share.

Competitive Moat

JNJ

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets (Patents, Brand Recognition for pharmaceutical products, consumer brands, and medical devices)Switching Costs (High for complex medical devices and established drug therapies, particularly in hospital settings)Efficient Scale (Massive global R&D, manufacturing, and distribution infrastructure)

TERN

Rating

🛡️ None

Trend

➡️ Not Applicable

Investment Thesis

JNJ1.0/10

If Johnson & Johnson continues to deliver consistent mid-single-digit organic revenue growth, driven by key pharmaceutical products and strategic MedTech innovation, while maintaining its strong dividend and capital allocation discipline, then its valuation should remain stable or grow modestly, providing a reliable long-term investment for income and capital preservation. This thesis focuses on s...

Full JNJ Analysis

TERN0.1/10

The investment thesis for Terns Pharmaceuticals as a high-risk, high-reward 10x growth opportunity is entirely negated. The company was acquired by Merck for $53.00 per share and subsequently delisted on May 5, 2026. All independent growth potential has been capitalized and transferred to Merck. Terns no longer represents a viable investment for public equity investors.

Full TERN Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555.59 billion fundamentally restricts its ability to achieve 10x growth within a 3-5 year timeframe. Su...

Full JNJ Analysis

TERN0.1/10

Score Change Explanation: The score has been maintained at an extremely low level (0/100, down from the previous 1/100) to reflect the definitive and irreversible change in Terns Pharmaceuticals' status. On May 5, 2026, Merck completed its acquisition of TERN for $53.00 per share, and the company has since been delisted from Nasdaq. This corporate action entirely eliminates TERN's independent existence as a public company and, consequently, any possibility of it generating 10x growth for public ...

Full TERN Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.